Senseonics Takes the Stage at Healthcare Conference
GERMANTOWN, Md. -- Senseonics Holdings, Inc. (NYSE American: SENS), recognized for its innovative approach in diabetes care, will actively participate in the esteemed TD Cowen's 45th Annual Health Care Conference, scheduled to take place in Boston. This event serves as a crucial platform for Senseonics, allowing them to connect with potential investors and showcase their groundbreaking technology designed to aid individuals managing diabetes.
Event Details and Format
The upcoming conference promises to be informative, featuring a corporate overview and personalized one-on-one meetings, enabling in-depth discussions about Senseonics' vision and innovations. Set for Tuesday, March 4, 2025, at 3:10 PM ET, attendees can expect a comprehensive insight into the workings of the company and its contributions to healthcare.
Accessing the Conference
For those interested in following along, a live webcast will be available, allowing participants to engage with the presentation remotely. This accessibility ensures that those who cannot attend in person can still gain valuable insights into Senseonics and its future endeavors in diabetes management.
About Senseonics and Its Transformational Technology
Senseonics is not just a player in the diabetes management sphere; it is a pioneer. The company's focus is on creating advanced glucose monitoring products, aimed at transforming lives and enhancing the quality of life for those within the diabetes community. Their featured products, the Eversense® 365 and Eversense® E3, exemplify cutting-edge technology, utilizing a small sensor that is implanted under the skin. This sensor wirelessly communicates with a smart transmitter, ensuring users have constant access to critical glucose data delivered directly to their smartphones every five minutes.
Advancements in Glucose Monitoring
This innovation highlights Senseonics' commitment to providing accurate and reliable glucose monitoring solutions. Their long-term implantable CGM systems stand out in the market, providing patients with an advanced tool for better diabetes management, something that can ultimately improve health outcomes and quality of life.
Connecting with Investors
Investor relations are a crucial aspect of Senseonics' strategy. The company encourages stakeholders and interested parties to reach out for more information regarding its products and developments. Jeremy Feffer, reaching out through LifeSci Advisors, serves as the point of contact for investors wishing to learn more about Senseonics and its innovative pathways in diabetes care.
Contact Information for Investors
Should you have inquiries or require deeper insights into the workings and future aspirations of Senseonics, you can contact Jeremy Feffer via email at investors@senseonics.com. This direct line ensures that all questions are answered, fostering transparency and trust with the investor community.
Frequently Asked Questions
What is the TD Cowen Annual Health Care Conference?
The TD Cowen Annual Health Care Conference is a prominent event that brings together industry leaders to discuss advancements, share insights, and foster investor relations in the healthcare sector.
What are the main products offered by Senseonics?
Senseonics specializes in long-term implantable continuous glucose monitoring (CGM) systems, notably the Eversense® 365 and Eversense® E3, which help patients manage diabetes effectively.
How can investors participate in the conference?
Investors can participate by attending the conference in person or tuning into the live webcast that will be made available during the event.
Who should I contact for investor relations at Senseonics?
Jeremy Feffer from LifeSci Advisors is the designated contact for investor relations, and he can be reached at investors@senseonics.com.
What is the significance of the new CGM technology from Senseonics?
The new CGM technology developed by Senseonics is significant as it offers a reliable, less intrusive method for continuous glucose monitoring, which can significantly enhance the lives of those managing diabetes.
